Formulary Search Results for: CALCIUM AND VITAMIN D
7.2.2 Vaginal and vulval infections - View Category
Restrictions:
The treatment of bacterial vaginosis is restricted to use in patients for whom the initial treatment is not effective or well tolerated.
7.4.2 Drugs for urinary frequency, enuresis, and incontinence - View Category
Restrictions:
Desmopressin oral lyophilisate for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults is restricted to specialist initiation by a consultant gynaecologist/urogynaecologist for use in patients aged 65 years and above (also see prescribing notes below).
Prescribing Notes:
- A positive diagnosis should be made following analysis of a 3-day volume chart
- Assessment of efficacy is required every 3 months
- Monitoring arrangements will be the responsibility of secondary care
7.4.2 Drugs for urinary frequency, enuresis, and incontinence - View Category
Prescribing Notes:
Pelvic floor exercises are considered the first line treatment for stress incontinence in women.
6.4.2 Male sex hormones and antagonists - View Category
5.1.3 Tetracyclines - View Category
Prescribing Notes:
Doxycycline is no more effective than oxytetracycline and is several times more expensive. Uses include sinusitis and pelvic inflammatory disease.
5.3.1.1 Nucleoside reverse transcriptase inhibitors - View Category
Restrictions:
Restricted to use by HIV specialists.
Prescribing Notes:
For treatment of hepatitis B see section 5.3.3.
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
Restricted to use by HIV specialists.
Prescribing Notes:
Please note: Only this combination preparation containing cobicistat is included in the Formulary. Cobicistat tablets as a separate preparation (Tybost®) are not recommended for use by the Scottish Medicines Consortium and are non-Formulary.
4.1.1.1 Hypnotics for acute insomnia - View Category
4.1.2 Anxiolytics - View Category
4.3.4 Other antidepressant drugs - View Category
Restrictions:
Restricted to psychiatrist initiation only as a third line therapy for major depressive episodes. The SMC has not recommended its use for generalised anxiety disorders.